Neurogene Inc. 8-K

What Happened

• Neurogene Inc. announced a public offering under an underwriting agreement dated June 30, 2026. The offering included 3,500,000 shares of common stock at $30.00 per share and, in lieu of shares to certain investors, pre‑funded warrants to purchase up to 666,666 shares at $29.999999 per warrant (exercise price $0.000001).
• The underwriters had a 30‑day option to purchase up to an additional 624,999 shares, which they exercised in full on July 1, 2026. The offering was expected to close on July 2, 2026. Net proceeds, after discounts, commissions and expenses, are expected to be approximately $134.8 million.

Key Details

• Offering price: $30.00 per common share; Pre‑Funded Warrant price: $29.999999 (exercise price $0.000001).
• Shares initially offered: 3,500,000 common shares; Pre‑Funded Warrants: up to 666,666; Option exercised for additional 624,999 shares.
• Ownership limits on warrant exercise: holders may not exercise if it would push beneficial ownership above 4.99% (or 9.99% as applicable); holders can elect up to 19.99% with 61 days’ prior notice.
• The offering was made from a shelf registration effective April 4, 2025; a final prospectus supplement was filed June 30, 2026.

Why It Matters

• The offering provides Neurogene with fresh capital to fund operations: the company says the net proceeds plus existing cash should fund operating expenses and capital needs into Q1 2029. For investors, that extends the company’s cash runway and supports ongoing development programs.
• The issuance is dilutive to existing shareholders (new shares and potential warrant exercises), and the underwriters’ full option exercise increased the share count sold. The ownership caps on pre‑funded warrants limit concentration by large holders.